Yuxi Jiuzhou Biotechnology

Yuxi Jiuzhou Biotechnology Co., Ltd. is a specialized biopharmaceutical manufacturer based in Yuxi, Yunnan Province, China, and operates as a wholly-owned subsidiary of Walvax Biotechnology. The company is primarily focused on the production and commercialization of human vaccines, with its flagship product being a freeze-dried live attenuated Hepatitis A vaccine. This vaccine achieved a significant milestone in 2017 by receiving World Health Organization (WHO) Pre-qualification, enabling its distribution through international agencies like UNICEF. Yuxi Jiuzhou maintains advanced manufacturing facilities that adhere to international Good Manufacturing Practice (GMP) standards. As a key component of the Walvax group, the company supports the broader mission of providing affordable and effective immunization solutions globally. Its operations are integrated into the parent company's extensive research, development, and supply chain networks.